https://www.pharmaradar360.com/article/ukhsa-updates-heat-health-alerts-across-england-ed2386aedcea3cbcPharma Surgeen2026-08-02T14:44:11.000ZUKHSA updates heat health alerts across Englandhttps://www.pharmaradar360.com/article/this-mad-scientist-built-india-s-first-pharmaceutical-company-made-major-discove-cc17bd33ba1c5925Pharma Surgeen2026-08-02T14:02:13.000ZTHIS ‘mad scientist’ built India’s first pharmaceutical company, made major discoveries in Chemistry, donated entire fortune to charity, his name was…https://www.pharmaradar360.com/article/study-hiv-injectable-drug-offers-pregnant-lactating-mothers-100-protection-fd8a9e947cd3f2f2Pharma Surgeen2026-08-02T13:00:59.000ZSTUDY: HIV injectable drug offers pregnant, lactating mothers 100% protectionhttps://www.pharmaradar360.com/article/union-minister-rajiv-ranjan-singh-stresses-research-in-pharma-and-biotech-sector-6900c5ef1cdf19fcPharma Surgeen2026-08-02T12:57:41.000ZUnion Minister Rajiv Ranjan Singh stresses research in pharma and biotech sectors | Akashvani Newshttps://www.pharmaradar360.com/article/senate-panel-will-examine-biotech-s-role-in-u-s-health-resilience-b12f7b7387463c14Pharma Surgeen2026-08-02T12:28:52.000ZSenate Panel Will Examine Biotech's Role in U.S. Health Resiliencehttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-zhejiang-shouxiangu-pharmaceutical-holding-c-656387bdd0f2cc33Pharma Surgeen2026-08-02T11:55:25.000ZEnterprise value to EBIT forward of Zhejiang Shouxiangu Pharmaceutical Holding Co. Ltd. Class A – SSE:603896https://www.pharmaradar360.com/article/5-biotech-stocks-that-delivered-big-gains-key-catalysts-ahead-for-qure-cdna-adpt-09bb6aed56c386c1Pharma Surgeen2026-08-02T10:54:00.000Z5 Biotech Stocks That Delivered Big Gains - Key Catalysts Ahead For QURE, CDNA, ADPT, ELVN & AMLXhttps://www.pharmaradar360.com/article/hoth-s-pivot-from-biotech-to-space-tech-sparks-massive-rally-in-stock-retail-und-fea1a8d486dec34bPharma Surgeen2026-08-02T10:48:49.000ZHOTH’s Pivot From Biotech To Space Tech Sparks Massive Rally In Stock – Retail Underlines Importance Of Securing Fresh Dealshttps://www.pharmaradar360.com/article/kelun-pharmaceutical-002422-sz-multiple-drug-products-provisionally-awarded-in-t-ec5ed1e2d068e3bdPharma Surgeen2026-08-02T10:23:12.000ZKelun Pharmaceutical (002422.SZ): Multiple drug products provisionally awarded in the 12th batch of national centralized drug procurementhttps://www.pharmaradar360.com/article/my-job-is-to-ensure-safe-food-fda-chief-warns-of-wider-crackdown-after-restauran-84c9f26061c96b9ePharma Surgeen2026-08-02T09:47:37.000Z'My job is to ensure safe food': FDA chief warns of wider crackdown after restaurant hygiene inspectionshttps://www.pharmaradar360.com/article/etfs-investing-in-zhejiang-starry-pharmaceutical-co-ltd-class-a-stocks-6efc76bc1b8fbb75Pharma Surgeen2026-08-02T09:24:49.000ZETFs Investing in Zhejiang Starry Pharmaceutical Co., Ltd. Class A Stockshttps://www.pharmaradar360.com/article/a-who-was-taking-a-treatment-for-dyslipidemia-lipidemia-recently-saw-that-the-na-4d8db33b79dcc375Pharma Surgeen2026-08-02T08:47:41.000ZA, who was taking a treatment for dyslipidemia (lipidemia), recently saw that the name of the drug c..https://www.pharmaradar360.com/article/the-pharmaceutical-industry-is-expanding-retro-marketing-with-the-history-of-lon-72ff8e3f7ad82859Pharma Surgeen2026-08-02T08:44:50.000ZThe pharmaceutical industry is expanding "retro marketing" with the history of long-lived brands and..https://www.pharmaradar360.com/article/maharashtra-fda-chief-vows-stricter-action-against-hygiene-medicine-norm-violati-a604a85fa4139346Pharma Surgeen2026-08-02T08:39:16.000ZMaharashtra FDA chief vows stricter action against hygiene, medicine norm violationshttps://www.pharmaradar360.com/article/amgen-amgn-partners-with-mrbeast-to-fund-pediatric-cancer-research-and-reach-500-2d74ff7aa3cf822fPharma Surgeen2026-08-02T08:15:46.000ZAmgen (AMGN) Partners With MrBeast To Fund Pediatric Cancer Research And Reach 500 Million Subscribershttps://www.pharmaradar360.com/article/why-is-maharashtra-fda-targeting-restaurants-commissioner-tukaram-mundhe-explain-66ab71c1d13f28d3Pharma Surgeen2026-08-02T08:10:21.000ZWhy Is Maharashtra FDA Targeting Restaurants? Commissioner Tukaram Mundhe Explainshttps://www.pharmaradar360.com/article/ppb-chair-munyu-calls-for-ethical-practice-as-kenya-advances-pharmaceutical-refo-d114ff4715d387a6Pharma Surgeen2026-08-02T07:53:00.000ZPPB chair Munyu calls for ethical practice as Kenya advances pharmaceutical reformshttps://www.pharmaradar360.com/article/dr-reddy-s-gets-usfda-nod-for-rituximab-biosimilar-89b7034eadc010f7Pharma Surgeen2026-08-02T07:34:35.000ZDr. Reddy's Gets USFDA Nod for Rituximab Biosimilarhttps://www.pharmaradar360.com/article/the-clinical-trial-that-asks-whether-your-current-treatment-should-exist-32b3fdfc0f99c6daPharma Surgeen2026-08-02T07:28:08.000ZThe Clinical Trial That Asks Whether Your Current Treatment Should Existhttps://www.pharmaradar360.com/article/ntla-stock-surges-35-overnight-retail-mood-peaks-ahead-of-first-ever-phase-3-rea-d5beb93535a18e5ePharma Surgeen2026-08-02T07:21:30.000ZNTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapyhttps://www.pharmaradar360.com/article/sls-stock-hits-over-3-year-high-as-aml-drug-trial-nears-final-readout-wall-stree-d690b1c596b74875Pharma Surgeen2026-08-02T07:07:40.000ZSLS Stock Hits Over 3-Year High As AML Drug Trial Nears Final Readout — Wall Street Sees 30% More Upsidehttps://www.pharmaradar360.com/article/gas-crisis-strikes-paracetamol-api-other-industries-03fc12f35536dfe1Pharma Surgeen2026-08-02T06:04:23.000ZGas crisis strikes paracetamol API, other industrieshttps://www.pharmaradar360.com/article/case-biotech-research-sowing-seeds-for-jamaica-s-future-660a5137ad7be6a5Pharma Surgeen2026-08-02T06:04:11.000ZCASE biotech research sowing seeds for Jamaica’s futurehttps://www.pharmaradar360.com/article/price-to-sales-forward-of-protect-pharmaceutical-corp-otc-prtt-def4c2ab610055fdPharma Surgeen2026-08-02T05:51:54.000ZPrice to sales forward of Protect Pharmaceutical Corp – OTC:PRTThttps://www.pharmaradar360.com/article/concord-biotech-q1-fy27-strong-growth-marred-by-sequential-decline-and-valuation-9acf88826b7b7460Pharma Surgeen2026-08-02T05:31:26.000ZConcord Biotech Q1 FY27: Strong Growth Marred by Sequential Decline and Valuation Concernshttps://www.pharmaradar360.com/article/matica-bio-zeroes-in-on-bridging-global-biotech-with-korea-795be978ba0a6b14Pharma Surgeen2026-08-02T05:21:08.000ZMatica Bio zeroes in on bridging global biotech with Koreahttps://www.pharmaradar360.com/article/tukaram-mundhe-explains-his-philosophy-as-fda-cracks-down-on-restaurants-my-role-e59e262a9ece9234Pharma Surgeen2026-08-02T05:17:46.000ZTukaram Mundhe Explains His Philosophy As FDA Cracks Down On Restaurants: 'My Role Is To...'https://www.pharmaradar360.com/article/medicamen-biotech-ltd-is-rated-sell-f7b5b6fe4af16e07Pharma Surgeen2026-08-02T05:05:44.000ZMedicamen Biotech Ltd is Rated Sellhttps://www.pharmaradar360.com/article/cramer-this-biotech-stock-could-be-worth-over-100-billion-on-an-fda-approval-bra-124a3cc586a9fa9ePharma Surgeen2026-08-02T05:00:37.000ZCramer: This Biotech Stock Could Be Worth Over $100 Billion On An FDA Approval Braves Standings (7nBNgCwFes)https://www.pharmaradar360.com/article/kathua-biotech-park-to-drive-innovation-jobs-across-j-k-north-india-jitendra-sin-21fcb876fbc77ec6Pharma Surgeen2026-08-02T04:17:16.000ZKathua Biotech Park to drive innovation, jobs across J&K, north India: Jitendra Singhhttps://www.pharmaradar360.com/article/govt-committed-to-building-globally-competitive-innovation-driven-pharma-sector-7ea9ff6bb1f753d6Pharma Surgeen2026-08-02T03:28:00.000ZGovt committed to building globally competitive, innovation-driven pharma sector: Piyush Goyalhttps://www.pharmaradar360.com/article/piyush-goyal-invites-global-pharma-firms-to-invest-in-india-b5bf561e4e00c67aPharma Surgeen2026-08-02T03:27:53.000ZPiyush Goyal invites global pharma firms to invest in Indiahttps://www.pharmaradar360.com/article/biotech-pro-testosterone-booster-reviews-real-user-insights-for-long-term-metabo-47fba996b9018eb6Pharma Surgeen2026-08-02T03:26:54.000ZBiotech Pro Testosterone Booster Reviews: Real User Insights for Long-Term Metabolic Health *arBxoRmlL*https://www.pharmaradar360.com/article/what-is-the-latest-treatment-for-erectile-dysfunction-2023-view-9zawavrxl-61c8f12446c27241Pharma Surgeen2026-08-02T03:02:30.000Zwhat is the latest treatment for erectile dysfunction 2023 - View 9zawaVRXlhttps://www.pharmaradar360.com/article/mounjaro-fda-approval-status-2026-clinical-weight-loss-data-and-doctor-recommend-e05d64b9262d491ePharma Surgeen2026-08-02T02:19:55.000ZMounjaro Fda Approval Status 2026: Clinical Weight Loss Data And Doctor Recommendations [ZkkgCv7lTTq]https://www.pharmaradar360.com/article/michael-explains-exciting-apitegromab-clinical-trial-ufo-files-j8htefim7t-a4b77ac71e3c8ab0Pharma Surgeen2026-08-02T02:12:16.000ZMichael Explains Exciting Apitegromab Clinical Trial Ufo Files (j8HtefIM7t)https://www.pharmaradar360.com/article/etfs-investing-in-samsung-pharmaceutical-co-ltd-stocks-6b3fe25790c69497Pharma Surgeen2026-08-02T01:51:33.000ZETFs Investing in SAMSUNG PHARMACEUTICAL.CO.,Ltd. Stockshttps://www.pharmaradar360.com/article/etfs-investing-in-xizang-weixinkang-pharmaceutical-co-ltd-class-a-stocks-dff793f4d1b9d951Pharma Surgeen2026-08-02T01:50:34.000ZETFs Investing in Xizang Weixinkang Pharmaceutical Co., Ltd. Class A Stockshttps://www.pharmaradar360.com/article/glp-1-obesity-drug-news-today-latest-advancements-and-clinical-breakthroughs-gw6-dc471a7fe6be6c3cPharma Surgeen2026-08-02T01:44:39.000ZGlp 1 Obesity Drug News Today: Latest Advancements And Clinical Breakthroughs [gw6cCHEEIHc]https://www.pharmaradar360.com/article/testrovax-testosterone-boosting-compound-90ct-by-novex-biotech-view-dwbsgefpa-6caaa358a8002823Pharma Surgeen2026-08-02T01:07:19.000Z# TestroVax Testosterone Boosting Compound 90ct by Novex Biotech - View dWBSGefPahttps://www.pharmaradar360.com/article/the-ultimate-guide-to-finding-the-cheapest-glp-1-without-insurance-costs-compoun-536d665e1e103b5dPharma Surgeen2026-08-02T00:53:59.000ZThe Ultimate Guide To Finding The Cheapest Glp 1 Without Insurance: Costs, Compounded Options, And Safety [MpalSXSTADx]https://www.pharmaradar360.com/article/court-rules-blocking-abortion-pill-site-justified-59667787ca317483Pharma Surgeen2026-08-02T00:53:38.000ZCourt Rules Blocking Abortion Pill Site Justifiedhttps://www.pharmaradar360.com/article/keto-blast-gummies-fda-what-the-regulations-really-mean-for-this-supplement-v3jg-f4f76269c4465f93Pharma Surgeen2026-08-02T00:49:31.000ZKeto Blast Gummies Fda: What The Regulations Really Mean For This Supplement [V3JGqoPlI6c]https://www.pharmaradar360.com/article/tension-has-been-running-high-in-the-global-pharmaceutical-industry-two-companie-d151e30148a1c80dPharma Surgeen2026-08-02T00:30:35.000ZTension has been running high in the global pharmaceutical industry. Two companies that dominate the..https://www.pharmaradar360.com/article/etfs-investing-in-nanjing-king-friend-biochemical-pharmaceutical-co-ltd-class-a-f38663ad4a773a64Pharma Surgeen2026-08-02T00:30:32.000ZETFs Investing in Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A Stockshttps://www.pharmaradar360.com/article/genbio-inc-to-participate-in-the-2026-asia-bio-partnering-forum-in-singapore-36ff03d0ccb520f5Pharma Surgeen2026-08-02T00:01:28.000ZGenBio Inc. to Participate in the 2026 Asia Bio Partnering Forum in Singaporehttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-34a00ada40e55abaPharma Surgeen2026-08-02T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-82556f86373965b4Pharma Surgeen2026-08-02T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-23c0926c2cb59916Pharma Surgeen2026-08-02T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-2219d060cc87639cPharma Surgeen2026-08-02T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-5ff3e7c250fcf4adPharma Surgeen2026-08-02T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-e0f2076050d33d85Pharma Surgeen2026-08-02T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-694c363a3f391b01Pharma Surgeen2026-08-02T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-4182a5a0bb2814b4Pharma Surgeen2026-08-02T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-2de08bbf931cc514Pharma Surgeen2026-08-02T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-85a475c39cb2f903Pharma Surgeen2026-08-02T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-d9ea824d3dd6cfb5Pharma Surgeen2026-08-02T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-711c0e8ceb6afe4ePharma Surgeen2026-08-02T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-b5d902a2dadbd887Pharma Surgeen2026-08-02T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-e493df6124da02e1Pharma Surgeen2026-08-02T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/work-related-quality-of-life-and-its-demographic-correlates-among-nurse-educator-345248ec12d07e41Pharma Surgeen2026-08-02T00:00:00.000ZWork-Related Quality of Life and Its Demographic Correlates among Nurse Educators and Clinical Instructors in Philippine Higher Education Institutions: A Descriptive-Correlational Studyhttps://www.pharmaradar360.com/article/the-relationship-between-legal-instructions-and-factual-circumstances-in-a-jury-eca40a6464a4bedfPharma Surgeen2026-08-02T00:00:00.000ZTHE RELATIONSHIP BETWEEN LEGAL INSTRUCTIONS AND FACTUAL CIRCUMSTANCES IN A JURY TRIALhttps://www.pharmaradar360.com/article/clinical-and-molecular-study-of-upper-respiratory-tract-infections-caused-by-kle-b31dec8fe4eadd6cPharma Surgeen2026-08-02T00:00:00.000ZCLINICAL AND MOLECULAR STUDY OF UPPER RESPIRATORY TRACT INFECTIONS CAUSED BY KLEBSIELLA PNEUMONIAE IN CATShttps://www.pharmaradar360.com/article/the-effects-of-combined-periodontal-and-orthodontic-treatment-in-periodontally-c-8daaad2d4417293ePharma Surgeen2026-08-02T00:00:00.000ZThe Effects of Combined Periodontal and Orthodontic Treatment in Periodontally Compromised Adult Patients: A Longitudinal Clinical Studyhttps://www.pharmaradar360.com/article/clinical-approaches-to-non-ordinary-experiences-noes-scoping-review-and-bibliome-e7f1148c3a3e3cd9Pharma Surgeen2026-08-02T00:00:00.000ZClinical Approaches to Non-Ordinary Experiences (NOEs): scoping review and bibliometric analysishttps://www.pharmaradar360.com/article/perceptions-and-practices-of-medical-interns-on-clinical-empathy-3b2f16f191e564b6Pharma Surgeen2026-08-02T00:00:00.000ZPerceptions and Practices of Medical Interns on Clinical Empathyhttps://www.pharmaradar360.com/article/association-of-the-lt-i-gt-t-53-pro72arg-lt-i-gt-polymorphism-with-lymphovascula-59bc4cd9c81c6fa1Pharma Surgeen2026-08-02T00:00:00.000ZAssociation of the <i>TР53 Pro72Arg</i> polymorphism with lymphovascular space invasion and survival in cervical cancerhttps://www.pharmaradar360.com/article/improvement-in-lipid-profile-and-sex-hormones-with-oleoylethanolamide-supplement-cb68a165324e2dabPharma Surgeen2026-08-02T00:00:00.000ZImprovement in Lipid Profile and Sex Hormones with Oleoylethanolamide Supplement in Women with Polycystic Ovary Syndrome: A Clinical Trialhttps://www.pharmaradar360.com/article/the-effect-of-moderate-intensity-crossfit-training-on-serum-vitamin-d-levels-and-1f851af11331ecccPharma Surgeen2026-08-02T00:00:00.000ZThe Effect of Moderate Intensity CrossFit Training on Serum Vitamin D Levels and Anthropometric Measures in Overweight/Obese Adult Women: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/knowledge-awareness-and-attitudes-toward-food-drug-interactions-among-a-sample-o-ae8cd282adeaa6b1Pharma Surgeen2026-08-02T00:00:00.000ZKnowledge, Awareness, and Attitudes toward Food–Drug Interactions among a Sample of the Iraqi Population in Baghdad: A Cross-Sectional Studyhttps://www.pharmaradar360.com/article/proximal-type-epithelioid-sarcoma-of-the-vulva-a-case-report-422a2b63e39e609aPharma Surgeen2026-08-02T00:00:00.000ZProximal Type” Epithelioid Sarcoma of the Vulva: A Case Reporthttps://www.pharmaradar360.com/article/functional-urinary-retention-in-children-and-adolescents-acase-report-fd1274ff3667ee9aPharma Surgeen2026-08-02T00:00:00.000ZFunctional Urinary Retention in Children and Adolescents: ACase Reporthttps://www.pharmaradar360.com/article/cholangiocellular-cancer-metastasis-in-the-terminal-ileum-a-case-report-ac0f63a6ac0d1d0dPharma Surgeen2026-08-02T00:00:00.000ZCholangiocellular Cancer Metastasis in the Terminal Ileum: A Case Reporthttps://www.pharmaradar360.com/article/management-of-daunorubicin-extravasation-with-dexrazoxane-in-a-child-47e75ebad289851cPharma Surgeen2026-08-02T00:00:00.000ZManagement of Daunorubicin Extravasation with Dexrazoxane in a Childhttps://www.pharmaradar360.com/article/a-confluence-of-autoimmunity-in-a-male-patient-severe-hypothyroidism-with-massiv-6caab5382092402dPharma Surgeen2026-08-02T00:00:00.000ZA Confluence of Autoimmunity in a Male Patient: Severe Hypothyroidism with Massive Pericardial Effusion, Sjögren’s Syndrome, and Vasculitishttps://www.pharmaradar360.com/article/extra-articular-tibia-vara-deformity-managed-with-kinematic-aligned-total-knee-a-3494ac0f325c97f0Pharma Surgeen2026-08-02T00:00:00.000ZExtra-Articular Tibia Vara Deformity Managed with Kinematic Aligned Total Knee Arthroplasty: A Case Reporthttps://www.pharmaradar360.com/article/percutaneous-endovascular-retrieval-of-an-embolized-chemotherapy-port-a-cath-fra-7e49f83d8e8fe113Pharma Surgeen2026-08-02T00:00:00.000ZPercutaneous Endovascular Retrieval of an Embolized Chemotherapy Port-A-Cath Fragment from the Superior Vena Cava Utilizing a Snare System: A Case Reporthttps://www.pharmaradar360.com/article/post-covid-19-complications-a-trigger-for-the-onset-of-depression-to-treatment-r-e1b2d5d93ef23e35Pharma Surgeen2026-08-02T00:00:00.000ZPost-COVID-19 Complications:A Trigger for the Onset of Depression to Treatment-Resistant Depression: A Case Reporthttps://www.pharmaradar360.com/article/clinical-utility-of-the-tamil-speech-in-noise-test-for-detecting-hidden-hearing-479bc4490a28fa58Pharma Surgeen2026-08-02T00:00:00.000ZClinical Utility of the Tamil Speech-in-Noise Test for Detecting Hidden Hearing Loss in Tinnitus with Normal Audiograms: Insights from Behavioral and Electrophysiological Measureshttps://www.pharmaradar360.com/article/mental-health-nursing-and-clinical-supervision-a-critical-discussion-of-key-issu-ce371292ac68e058Pharma Surgeen2026-08-02T00:00:00.000ZMental health nursing and clinical supervision: a critical discussion of key issues around international policy developmentshttps://www.pharmaradar360.com/article/the-first-72-hours-of-acute-pancreatitis-patterns-of-variability-in-early-clinic-a8efcb8d98e10620Pharma Surgeen2026-08-02T00:00:00.000ZThe first 72 hours of acute pancreatitis: patterns of variability in early clinical decision-makinghttps://www.pharmaradar360.com/article/clinical-determinants-of-neonatal-mortality-at-a-tertiary-hospital-in-a-resource-63eb86811fc72bf0Pharma Surgeen2026-08-02T00:00:00.000ZClinical determinants of neonatal mortality at a tertiary hospital in a resource limited setting: a retrospective cohort studyhttps://www.pharmaradar360.com/article/comparison-of-clinical-characteristics-and-outcomes-of-systemic-lupus-erythemato-431964f9d63c9d49Pharma Surgeen2026-08-02T00:00:00.000ZComparison of Clinical Characteristics and Outcomes of Systemic Lupus Erythematosus-associated Thrombotic Thrombocytopenic Purpura and Idiopathic Thrombotic Thrombocytopenic Purpura: A Single Centre Study from Eastern Indiahttps://www.pharmaradar360.com/article/workplace-violence-in-indonesian-clinical-learning-environments-cultural-and-org-c3e8849246cb6696Pharma Surgeen2026-08-02T00:00:00.000ZWorkplace Violence in Indonesian Clinical Learning Environments: Cultural and Organisational Contexts Shaping Nursing Students' Experienceshttps://www.pharmaradar360.com/article/in-vitro-antiamoebic-activity-of-novel-metronidazole-derivatives-and-silver-nano-09045b171394c5b0Pharma Surgeen2026-08-02T00:00:00.000ZIn vitro antiamoebic activity of novel metronidazole derivatives and silver nanoparticle formulations against clinical isolates of Entamoeba histolyticahttps://www.pharmaradar360.com/article/clinical-and-functional-outcomes-of-bone-defect-reconstruction-using-the-masquel-ba7c88c79a63570aPharma Surgeen2026-08-02T00:00:00.000ZClinical and Functional Outcomes of Bone Defect Reconstruction Using the Masquelet Technique: Experience with Rare Talus and Metatarsal Caseshttps://www.pharmaradar360.com/article/liposomal-bupivacaine-incisional-infiltration-for-postoperative-analgesia-after-f2d1db30bb27f94fPharma Surgeen2026-08-02T00:00:00.000ZLiposomal Bupivacaine Incisional Infiltration for Postoperative Analgesia After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy: A Randomized Placebo-Controlled Trialhttps://www.pharmaradar360.com/article/a-radiotherapy-related-fibrosis-gene-signature-based-risk-model-for-predicting-p-b237f07fd4a9ac55Pharma Surgeen2026-08-02T00:00:00.000ZA radiotherapy-related fibrosis gene signature-based risk model for predicting prognosis and immunological features in lung adenocarcinomahttps://www.pharmaradar360.com/article/additional-effects-of-group-training-and-online-exercise-to-a-12-week-online-pac-d5c897d5f6908f3bPharma Surgeen2026-08-02T00:00:00.000ZAdditional effects of group training and online exercise to a 12-week online pacing and education module on health-related quality of life in adult patients with post COVID-19: a randomized controlled trialhttps://www.pharmaradar360.com/article/ai-automation-of-statistical-analysis-plans-in-clinical-trials-7ed23ec41ca67d2aPharma Surgeen2026-08-02T00:00:00.000ZAI Automation of Statistical Analysis Plans in Clinical Trialshttps://www.pharmaradar360.com/article/improving-hospital-process-management-through-process-mining-a-case-study-on-cov-7f4c3050870dc43fPharma Surgeen2026-08-02T00:00:00.000ZImproving Hospital Process Management Through Process Mining: A Case Study on COVID-19 Clinical Pathwayshttps://www.pharmaradar360.com/article/pills-and-perspectives-decoding-stance-on-drug-use-with-the-rxtance-dataset-07e6f2a2ecd03424Pharma Surgeen2026-08-02T00:00:00.000ZPills and Perspectives: Decoding Stance on Drug Use with the Rxtance Datasethttps://www.pharmaradar360.com/article/clinical-impact-of-gleason-pattern-5-on-doublet-versus-triplet-therapy-in-metast-5dca45945af00d31Pharma Surgeen2026-08-02T00:00:00.000ZClinical Impact of Gleason Pattern 5 on Doublet Versus Triplet Therapy in Metastatic Hormone‐Sensitive Prostate Cancerhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-jinghua-pharmaceutical-group-co-ltd-class-a-szse-00-11779d5399f32e7ePharma Surgeen2026-08-01T23:25:40.000ZPrice to earnings forward of Jinghua Pharmaceutical Group Co., Ltd. Class A – SZSE:002349https://www.pharmaradar360.com/article/fss-moves-to-end-inflated-biotech-tech-transfer-disclosures-a9c7730a8f13cc31Pharma Surgeen2026-08-01T23:09:00.000ZFSS moves to end inflated biotech tech-transfer disclosureshttps://www.pharmaradar360.com/article/north-indias-first-biotech-park-at-kathua-to-emerge-as-hub-of-innovation-agri-en-511161ca5f372c15Pharma Surgeen2026-08-01T22:55:52.000ZNorth Indias first Biotech Park at Kathua to emerge as hub of innovation, agri entrepreneurs: Dr Jitendrahttps://www.pharmaradar360.com/article/rtw-biotech-opportunities-ltd-usd-revenue-breakdown-aquisuk-rtwl-b99b7bf4a9d4b8b0Pharma Surgeen2026-08-01T22:37:57.000ZRTW Biotech Opportunities Ltd USD Revenue Breakdown – AQUISUK:RTWLhttps://www.pharmaradar360.com/article/fda-approval-of-glp-1-medications-the-ultimate-guide-to-regulatory-milestones-an-97b5842cf540a4d3Pharma Surgeen2026-08-01T22:20:22.000ZFda Approval Of Glp 1 Medications: The Ultimate Guide To Regulatory Milestones And Clinical Impact [VZWtPYB6BTg]https://www.pharmaradar360.com/article/does-kb801-s-single-patient-signal-and-s-p-400-move-change-the-bull-case-for-kry-204005f49fe08ae1Pharma Surgeen2026-08-01T22:20:19.000ZDoes KB801’s Single-Patient Signal And S&P 400 Move Change The Bull Case For Krystal Biotech (KRYS)?https://www.pharmaradar360.com/article/xlv-vs-ibbq-is-broad-healthcare-exposure-or-biotech-growth-the-better-etf-buy-7bbbc1ec110c31e5Pharma Surgeen2026-08-01T22:11:00.000ZXLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy?https://www.pharmaradar360.com/article/ono-pharmaceutical-tse-4528-stock-holds-appeal-despite-revenue-retreat-61102a46a4e27a40Pharma Surgeen2026-08-01T21:43:01.000ZOno Pharmaceutical (TSE:4528) Stock Holds Appeal Despite Revenue Retreathttps://www.pharmaradar360.com/article/etfs-investing-in-xiangxue-pharmaceutical-co-ltd-class-a-stocks-c301cd62fdc6835cPharma Surgeen2026-08-01T21:08:25.000ZETFs Investing in Xiangxue Pharmaceutical Co., Ltd. Class A Stockshttps://www.pharmaradar360.com/article/novo-nordisk-s-failed-heart-drug-trial-wipes-out-20-5-billion-in-market-value-f7f3079cc7639afdPharma Surgeen2026-08-01T20:31:59.000ZNovo Nordisk's Failed Heart Drug Trial Wipes Out $20.5 Billion in Market Valuehttps://www.pharmaradar360.com/article/pangen-biotech-inc-revenue-breakdown-krx-222110-4200ca6c479aa324Pharma Surgeen2026-08-01T20:29:43.000ZPanGen Biotech, Inc. Revenue Breakdown – KRX:222110https://www.pharmaradar360.com/article/legend-biotech-ceo-resigns-merck-deletes-trial-hint-and-fda-clears-novel-adhd-dr-83d92e05b6fe0b64Pharma Surgeen2026-08-01T20:19:42.000ZLegend Biotech CEO Resigns, Merck Deletes Trial Hint, And FDA Clears Novel ADHD Drughttps://www.pharmaradar360.com/article/kathua-biotech-park-to-drive-innovation-jobs-across-north-india-jitendra-singh-daf73a8438d16eb9Pharma Surgeen2026-08-01T19:55:49.000ZKathua Biotech Park to drive innovation, jobs across North India: Jitendra Singhhttps://www.pharmaradar360.com/article/trump-proposes-generic-drug-tariffs-effective-2028-signaling-fresh-push-to-resho-ea27d5bfc519669aPharma Surgeen2026-08-01T19:51:46.000ZTrump Proposes Generic Drug Tariffs Effective 2028, Signaling Fresh Push to Reshore Pharmaceutical Production - GAAP Earnings Reporthttps://www.pharmaradar360.com/article/ember-lifesciences-and-alfresa-corp-to-improve-quality-of-pharmaceutical-cold-ch-daf585b07e5c70f7Pharma Surgeen2026-08-01T19:38:48.000ZEmber LifeSciences and Alfresa Corp to improve quality of pharmaceutical cold chain in Japanhttps://www.pharmaradar360.com/article/xlv-vs-pbe-is-a-low-cost-healthcare-etf-the-better-buy-than-a-focused-biotech-sp-6e26dc6291560cbbPharma Surgeen2026-08-01T18:57:00.000ZXLV vs PBE: Is a Low-Cost Healthcare ETF the Better Buy Than a Focused Biotech Specialist?https://www.pharmaradar360.com/article/pharmaceutical-pollution-needs-to-be-stopped-f91a3b0deecd6da7Pharma Surgeen2026-08-01T18:43:57.000ZPharmaceutical pollution needs to be stoppedhttps://www.pharmaradar360.com/article/xlv-vs-pbe-healthcare-sector-stability-vs-biotech-growth-ad6d67439c85ea21Pharma Surgeen2026-08-01T18:38:00.000ZXLV vs PBE: Healthcare Sector Stability vs Biotech Growthhttps://www.pharmaradar360.com/article/anlon-healthcare-achieves-triple-digit-growth-in-q1-fy27-strengthens-integrated-ce8a7c8848b958c2Pharma Surgeen2026-08-01T18:27:00.000ZAnlon Healthcare Achieves Triple-Digit Growth in Q1 FY27, Strengthens Integrated Pharma Platformhttps://www.pharmaradar360.com/article/collegium-pharmaceutical-pain-cash-flows-are-funding-an-adhd-re-rating-nasdaq-co-9abc90c272f7f50ePharma Surgeen2026-08-01T18:12:27.000ZCollegium Pharmaceutical: Pain Cash Flows Are Funding An ADHD Re-Rating (NASDAQ:COLL)https://www.pharmaradar360.com/article/iba-beximco-launch-first-executive-prog-for-pharma-professionals-1b04577955976ad8Pharma Surgeen2026-08-01T18:00:00.000ZIBA, Beximco launch first executive prog for pharma professionalshttps://www.pharmaradar360.com/article/6-reasons-pharma-manufacturing-has-eyes-on-puerto-rico-1eb4117c56b21852Pharma Surgeen2026-08-01T16:58:29.000Z6 Reasons Pharma Manufacturing Has Eyes On Puerto Ricohttps://www.pharmaradar360.com/article/mou-signed-to-operationalise-north-india-s-first-industrial-biotech-park-in-kath-80282e81f07c899cPharma Surgeen2026-08-01T16:28:12.000ZMoU Signed to Operationalise North India’s First Industrial Biotech Park in Kathua; Dr Jitendra Singh Calls it a Major Boost for J&K’s Biotechnology Ecosystemhttps://www.pharmaradar360.com/article/concord-biotech-q1-fy27-revenue-jumps-26-to-257-5-crore-cbc0c948de170e97Pharma Surgeen2026-08-01T16:04:09.000ZConcord Biotech: Q1 FY27 Revenue Jumps 26% to ₹257.5 Crorehttps://www.pharmaradar360.com/article/pharmaceutical-safety-review-2026-exposes-why-pills-to-lose-weight-rarely-delive-6e3a9fb0b26beef9Pharma Surgeen2026-08-01T15:25:22.000ZPharmaceutical Safety Review 2026 Exposes Why Pills To Lose Weight Rarely Deliver Lasting Results [SAwa8ztf72m]https://www.pharmaradar360.com/article/bharat-biotech-md-calls-on-students-to-contribute-meaningfully-to-society-7c6bca1c66a1e8bdPharma Surgeen2026-08-01T15:20:01.000ZBharat Biotech MD calls on students to contribute meaningfully to societyhttps://www.pharmaradar360.com/article/a-new-adhd-drug-just-got-fda-approval-here-s-what-makes-it-different-9564906794f54dfbPharma Surgeen2026-08-01T15:06:08.000ZA new ADHD drug just got FDA approval. Here's what makes it different.https://www.pharmaradar360.com/article/the-5-most-interesting-analyst-questions-from-west-pharmaceutical-services-s-q2-4e293d35c7adb921Pharma Surgeen2026-08-01T14:59:57.000ZThe 5 Most Interesting Analyst Questions From West Pharmaceutical Services’s Q2 Earnings Callhttps://www.pharmaradar360.com/article/pfizer-s-litfulo-clears-two-phase-3-vitiligo-trials-paving-way-for-global-regula-8b338a80a65702e1Pharma Surgeen2026-08-01T14:24:34.000ZPfizer’s LITFULO clears two Phase 3 vitiligo trials paving way for global regulatory filingshttps://www.pharmaradar360.com/article/novo-nordisk-s-phase-3-zeus-trial-misses-cardiovascular-endpoint-for-ziltivekima-df5015a23170cf4bPharma Surgeen2026-08-01T14:24:34.000ZNovo Nordisk's Phase 3 ZEUS trial misses cardiovascular endpoint for Ziltivekimabhttps://www.pharmaradar360.com/article/how-should-clinicians-weigh-kidney-cancer-data-from-asco-2026-d78bb00c5277b027Pharma Surgeen2026-08-01T14:08:25.000ZHow Should Clinicians Weigh Kidney Cancer Data From ASCO 2026?https://www.pharmaradar360.com/article/north-china-pharmaceutical-company-ltd-class-a-revenue-breakdown-sse-600812-259d791f9fd24b04Pharma Surgeen2026-08-01T14:05:24.000ZNorth China Pharmaceutical Company Ltd. Class A Revenue Breakdown – SSE:600812https://www.pharmaradar360.com/article/redefining-hiv-management-emerging-antiretroviral-drug-classes-and-immunologic-s-f44fd6ab08b918ddPharma Surgeen2026-08-01T13:52:36.000ZRedefining HIV Management: Emerging Antiretroviral Drug Classes and Immunologic Strategies Shaping the Future of HIV Treatment, Preventionhttps://www.pharmaradar360.com/article/kathua-biotech-park-to-drive-innovation-jobs-in-j-k-north-india-3c6d734b433228a9Pharma Surgeen2026-08-01T13:50:51.000ZKathua Biotech Park to Drive Innovation & Jobs in J&K, North Indiahttps://www.pharmaradar360.com/article/concord-biotech-q1-results-net-profit-rises-31-yoy-to-57-7-crore-38d1c69e24514215Pharma Surgeen2026-08-01T13:35:39.000ZConcord Biotech Q1 Results: Net profit rises 31% YoY to ₹57.7 crorehttps://www.pharmaradar360.com/article/sichuan-kelun-biotech-biopharmaceutical-co-revenue-breakdown-otc-skbhf-958320008ec2c7baPharma Surgeen2026-08-01T13:25:29.000ZSICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO Revenue Breakdown – OTC:SKBHFhttps://www.pharmaradar360.com/article/top-portage-biotech-alp-competitors-2026-f77a722fc11c05f7Pharma Surgeen2026-08-01T13:11:35.000ZTop Portage Biotech (ALP) Competitors 2026https://www.pharmaradar360.com/article/exposing-the-most-dangerous-celebrity-skincare-launches-food-ej86yvxapf-ccc67ff46c2ca9e6Pharma Surgeen2026-08-01T13:08:23.000ZExposing The Most Dangerous Celebrity Skincare Launches Food (ej86YVXAPF)https://www.pharmaradar360.com/article/nafdac-joins-the-federal-ministry-of-health-and-social-welfare-nutrition-partner-59bc7b4ca73e2c7cPharma Surgeen2026-08-01T13:01:42.000ZNAFDAC joins the Federal Ministry of Health and Social Welfare, nutrition partners, and the global community in celebrating World Breastfeeding Week 2026https://www.pharmaradar360.com/article/the-third-dimension-of-antibody-therapy-078bced9c76afc8fPharma Surgeen2026-08-01T12:56:15.000ZThe Third Dimension of Antibody Therapyhttps://www.pharmaradar360.com/article/novo-nordisk-s-failed-heart-drug-trial-deepens-a-season-of-setbacks-c2a03fcd726aeb14Pharma Surgeen2026-08-01T12:53:11.000ZNovo Nordisk's Failed Heart Drug Trial Deepens a Season of Setbackshttps://www.pharmaradar360.com/article/concord-biotech-shareholders-approve-enhanced-loan-limits-at-agm-0f4a96d68b9b8506Pharma Surgeen2026-08-01T12:29:06.000ZConcord Biotech shareholders approve enhanced loan limits at AGMhttps://www.pharmaradar360.com/article/biotech-international-limited-reports-strong-fy2025-performance-b7463891495dd9efPharma Surgeen2026-08-01T12:00:00.000ZBiotech International Limited Reports Strong FY2025 Performancehttps://www.pharmaradar360.com/article/yemeni-honey-from-natural-resource-to-promising-pillar-for-pharmaceutical-indust-456b8166cf6df91bPharma Surgeen2026-08-01T11:52:00.000ZYemeni Honey: From Natural Resource to Promising Pillar for Pharmaceutical Industryhttps://www.pharmaradar360.com/article/karnataka-to-ban-junk-food-around-schools-25ea1f750a5cc074Pharma Surgeen2026-08-01T11:49:14.000ZKarnataka to ban junk food around schoolshttps://www.pharmaradar360.com/article/north-indias-first-industrial-biotech-park-at-kathua-to-drive-j-ks-biotechnology-691061b42535b24bPharma Surgeen2026-08-01T11:41:25.000ZNorth Indias First Industrial Biotech Park At Kathua To Drive J&Ks Biotechnology Revolution: Dr Jitendrahttps://www.pharmaradar360.com/article/north-india-s-first-biotech-park-at-kathua-a-hub-of-biotech-driven-entrepreneurs-74a6132819f1e003Pharma Surgeen2026-08-01T11:27:46.000ZNorth India’s First Biotech Park At Kathua, A Hub Of Biotech Driven Entrepreneurship In The Region: Dr. Jitendrahttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-kolmar-biotech-inc-krx-215380-c5226d0b372e4e11Pharma Surgeen2026-08-01T11:23:37.000ZEnterprise value to EBIT forward of Kolmar BioTech. Inc. – KRX:215380https://www.pharmaradar360.com/article/sun-pharma-shareholders-approve-all-resolutions-at-34th-agm-fb24251913c71d1ePharma Surgeen2026-08-01T11:19:39.000ZSun Pharma shareholders approve all resolutions at 34th AGMhttps://www.pharmaradar360.com/article/drug-repurposing-s-next-challenge-turning-discoveries-into-treatments-5ee7a0a69bf33feaPharma Surgeen2026-08-01T10:50:10.000ZDrug Repurposing’s Next Challenge: Turning Discoveries Into Treatmentshttps://www.pharmaradar360.com/article/why-drug-safety-has-become-india-s-next-pharmaceutical-imperative-0220321938f75a9fPharma Surgeen2026-08-01T10:46:53.000ZWhy Drug Safety Has Become India's Next Pharmaceutical Imperativehttps://www.pharmaradar360.com/article/janus-henderson-group-plc-has-145-08-million-position-in-teva-pharmaceutical-ind-9265df161f0885d9Pharma Surgeen2026-08-01T10:32:33.000ZJanus Henderson Group PLC Has $145.08 Million Position in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/rtw-biotech-opportunities-ltd-usd-revenue-breakdown-fwb-0bm-46c5c01c196fdc36Pharma Surgeen2026-08-01T10:18:15.000ZRTW Biotech Opportunities Ltd USD Revenue Breakdown – FWB:0BMhttps://www.pharmaradar360.com/article/over-1-500-experts-attended-the-hanoi-hospital-pharmaceutical-science-conference-f24c9beec4c56266Pharma Surgeen2026-08-01T10:14:49.000ZOver 1,500 experts attended the Hanoi Hospital Pharmaceutical Science Conference (expanded) in Nghe An.https://www.pharmaradar360.com/article/fluctuations-in-entrance-exam-scores-for-medical-and-pharmaceutical-schools-in-t-e6ac60587778fed9Pharma Surgeen2026-08-01T10:14:29.000ZFluctuations in entrance exam scores for medical and pharmaceutical schools in the North over the past 3 years, with "hot" majors exceeding 27 points.https://www.pharmaradar360.com/article/ebola-disease-caused-by-bundibugyo-virus-democratic-republic-of-the-congo-c7d412bd268a27acPharma Surgeen2026-08-01T10:13:28.000ZEbola disease caused by Bundibugyo virus - Democratic Republic of the Congohttps://www.pharmaradar360.com/article/krystal-biotech-inc-krys-valuation-pe-pb-fair-value-analysis-3b997157c5aec021Pharma Surgeen2026-08-01T09:37:27.000ZKrystal Biotech Inc (KRYS) Valuation: PE, PB & Fair Value Analysishttps://www.pharmaradar360.com/article/axiom-investment-management-llc-takes-965-000-position-in-teva-pharmaceutical-in-fdd38569a8949237Pharma Surgeen2026-08-01T08:40:51.000ZAxiom Investment Management LLC Takes $965,000 Position in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/vyloy-zolbetuximab-in-combination-with-chemotherapy-is-now-available-and-approve-726a3f2d1f11061aPharma Surgeen2026-08-01T08:37:23.000ZVYLOY (zolbetuximab) in combination with chemotherapy is NOW AVAILABLE and approved for first-line treatment of eligible* adult patients with gastric or gastroesophageal junction adenocarcinoma in Indiahttps://www.pharmaradar360.com/article/moleculin-biotech-mbrx-us-synthetic-expert-call-transcript-01-aug-2026-4388bb4781182970Pharma Surgeen2026-08-01T08:36:50.000ZMoleculin Biotech (MBRX US): Synthetic Expert Call Transcript (01 Aug 2026)https://www.pharmaradar360.com/article/sichuan-kelun-biotech-sehk-6990-wins-priority-review-for-sixth-sac-tmt-indicatio-3bcacf2c19b9ac8cPharma Surgeen2026-08-01T08:30:51.000ZSichuan Kelun Biotech (SEHK:6990) Wins Priority Review For Sixth Sac TMT Indicationhttps://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32Pharma Surgeen2026-08-01T07:49:04.000ZExcipient Selection Strategies to Mitigate Nitrosamine Riskshttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-teva-stake-boosted-by-avidity-partners-manage-cd336bd1caf2e954Pharma Surgeen2026-08-01T07:48:40.000ZTeva Pharmaceutical Industries Ltd. $TEVA Stake Boosted by Avidity Partners Management LPhttps://www.pharmaradar360.com/article/collegium-pharmaceutical-coll-us-will-release-its-earnings-report-before-the-mar-6463506595785845Pharma Surgeen2026-08-01T07:42:11.000ZCollegium Pharmaceutical (COLL.US) will release its earnings report before the market opens on August 6.https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-lushang-freda-pharmaceutical-co-ltd-class-1b3077d39a43419cPharma Surgeen2026-08-01T07:40:20.000ZEnterprise value to EBITDA forward of Lushang Freda Pharmaceutical Co., Ltd. Class A – SSE:600223https://www.pharmaradar360.com/article/vktx-launches-500m-shelf-after-full-enrollment-of-phase-3-obesity-drug-study-ret-eadccba4c246ddb9Pharma Surgeen2026-08-01T07:40:11.000ZVKTX Launches $500M Shelf After Full Enrollment Of Phase 3 Obesity Drug Study – Retail Bets On ‘Exceptionally Great Data’https://www.pharmaradar360.com/article/routine-health-data-is-outperforming-trial-data-for-ai-training-the-fda-hasn-t-c-d4d2eb28da80fedcPharma Surgeen2026-08-01T07:28:05.000ZRoutine Health Data Is Outperforming Trial Data for AI Training. The FDA Hasn’t Caught Up.https://www.pharmaradar360.com/article/is-reta-safe-ed612d1a92ee53f0Pharma Surgeen2026-08-01T06:57:07.000ZIs Reta Safe?https://www.pharmaradar360.com/article/vidipha-central-pharmaceutical-jsc-revenue-breakdown-hose-vdp-e54903770464339ePharma Surgeen2026-08-01T06:47:50.000ZVidipha Central Pharmaceutical JSC Revenue Breakdown – HOSE:VDPhttps://www.pharmaradar360.com/article/keros-receives-20m-milestone-as-elritercept-phase-3-trial-enrolls-first-patient-fd419735b9f7a212Pharma Surgeen2026-08-01T06:43:05.000ZKeros Receives $20M Milestone as Elritercept Phase 3 Trial Enrolls First Patienthttps://www.pharmaradar360.com/article/moleculin-biotech-updates-annamycin-data-prices-stock-offering-at-0-75-2f2af2ff3ce3d85ePharma Surgeen2026-08-01T06:43:05.000ZMoleculin Biotech updates Annamycin data, prices stock offering at $0.75https://www.pharmaradar360.com/article/karyopharm-s-selinexor-misses-primary-endpoint-in-phase-3-endometrial-cancer-tri-9b67a3c9e033d152Pharma Surgeen2026-08-01T06:33:05.000ZKaryopharm’s selinexor misses primary endpoint in Phase 3 endometrial cancer trialhttps://www.pharmaradar360.com/article/latest-glp-1-weight-loss-drug-news-today-breakthroughs-and-updates-b80xxamig4d-7fab59a491371951Pharma Surgeen2026-08-01T06:26:16.000ZLatest Glp 1 Weight Loss Drug News Today: Breakthroughs And Updates [B80XXaMIG4d]https://www.pharmaradar360.com/article/radiopharm-reports-positive-phase-2b-results-for-rad-101-imaging-agent-709215f45f30ba43Pharma Surgeen2026-08-01T06:08:56.000ZRadiopharm reports positive phase 2b results for RAD 101 imaging agenthttps://www.pharmaradar360.com/article/china-recruits-105-top-us-scientists-as-biotech-race-intensifies-db017f09367672edPharma Surgeen2026-08-01T05:49:33.000ZChina recruits 105 top US scientists as biotech race intensifieshttps://www.pharmaradar360.com/article/vktx-stock-lags-glp-1-peers-in-july-but-viking-ceo-says-its-obesity-drug-could-o-55e28e0768872cf0Pharma Surgeen2026-08-01T05:47:27.000ZVKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’thttps://www.pharmaradar360.com/article/why-drug-safety-has-become-india-s-next-pharmaceutical-imperative-fe7e802c10775113Pharma Surgeen2026-08-01T05:44:49.000ZWhy Drug Safety Has Become India's Next Pharmaceutical Imperativehttps://www.pharmaradar360.com/article/fda-crackdown-hotel-associations-urge-due-process-oppose-public-naming-before-le-201d60a95a5dc780Pharma Surgeen2026-08-01T05:14:22.000ZFDA Crackdown: Hotel Associations Urge Due Process, Oppose Public Naming Before Legal Proceedings Endhttps://www.pharmaradar360.com/article/maharashtra-fda-crackdown-why-hotel-bodies-want-modi-fadnavis-to-step-in-cdcf7311bca717efPharma Surgeen2026-08-01T05:12:17.000ZMaharashtra FDA crackdown: Why hotel bodies want Modi, Fadnavis to step inhttps://www.pharmaradar360.com/article/how-investors-are-reacting-to-disc-medicine-iron-balancing-larger-losses-with-ap-9f1e6ebd371dbad7Pharma Surgeen2026-08-01T04:37:19.000ZHow Investors Are Reacting To Disc Medicine (IRON) Balancing Larger Losses With APOLLO Phase 3 FDA Alignmenthttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-veraxa-biotech-ag-nasdaq-vrxa-9e43d26d8df8d00fPharma Surgeen2026-08-01T04:35:00.000ZEnterprise value to revenue forward of Veraxa Biotech AG – NASDAQ:VRXAhttps://www.pharmaradar360.com/article/oncolytics-biotech-nasdaq-oncy-trading-up-0-2-time-to-buy-f2e9503f70550445Pharma Surgeen2026-08-01T04:32:07.000ZOncolytics Biotech (NASDAQ:ONCY) Trading Up 0.2% - Time to Buy?https://www.pharmaradar360.com/article/mumbai-s-elite-clubs-lose-fssai-licences-after-fda-crackdown-a282362dc62461bcPharma Surgeen2026-08-01T04:30:00.000ZMumbai’s elite clubs lose FSSAI licences after FDA crackdownhttps://www.pharmaradar360.com/article/bombay-hc-slams-fda-over-untrue-clean-chit-to-mantralaya-canteen-after-lawyers-s-2235819edc0a6817Pharma Surgeen2026-08-01T04:23:38.000ZBombay HC slams FDA over "untrue" clean chit to Mantralaya canteen after lawyers' surprise inspection uncovers hygiene lapseshttps://www.pharmaradar360.com/article/novo-nordisk-s-august-reckoning-courtroom-battles-and-a-failed-heart-drug-conver-2423c536720ed46dPharma Surgeen2026-08-01T04:21:49.000ZNovo Nordisk's August Reckoning: Courtroom Battles and a Failed Heart Drug Convergehttps://www.pharmaradar360.com/article/create-medicines-expands-targeted-in-vivo-car-platform-through-strategic-researc-2d74a39b788189b5Pharma Surgeen2026-08-01T03:01:46.000ZCREATE medicines expands targeted in vivo CAR platform through strategic research collaboration and exclusive license agreement with Monash Universityhttps://www.pharmaradar360.com/article/daily-brief-health-care-moleculin-biotech-attovia-therapeutics-biostem-technolog-90829a4dcacff4c2Pharma Surgeen2026-08-01T02:02:05.000ZDaily Brief Health Care: Moleculin Biotech , Attovia Therapeutics, BioStem Technologies , Harbin Yuyantang Traditional Chinese Medicine Outpatient Group, Braveheart Bio, Vogenx, Apnimed and morehttps://www.pharmaradar360.com/article/ipo-databook-moleculin-biotech-mbrx-us-jul-2026-890a33dc59bc8dc3Pharma Surgeen2026-08-01T02:01:47.000ZIPO Databook: Moleculin Biotech (MBRX US) - Jul 2026https://www.pharmaradar360.com/article/price-to-sales-forward-of-samil-pharmaceutical-co-ltd-krx-000520-c223c21b3169a5a4Pharma Surgeen2026-08-01T01:54:35.000ZPrice to sales forward of Samil Pharmaceutical Co., Ltd. – KRX:000520https://www.pharmaradar360.com/article/blackrock-inc-trims-alumis-inc-alms-stake-amid-biotech-s-met-67744805cea9f09ePharma Surgeen2026-08-01T01:49:21.000ZBlackRock, Inc. Trims Alumis Inc (ALMS) Stake Amid Biotech's Methttps://www.pharmaradar360.com/article/h-c-wainwright-reiterates-inhibikase-stock-rating-on-fda-orphan-drug-status-45f83075f21c652dPharma Surgeen2026-08-01T01:45:40.000ZH.C. Wainwright reiterates Inhibikase stock rating on FDA orphan drug statushttps://www.pharmaradar360.com/article/novo-nordisk-misses-key-heart-outcomes-in-phase-3-shares-sink-10-chosunbiz-79aa02121ec86d9dPharma Surgeen2026-08-01T01:36:00.000ZNovo Nordisk misses key heart outcomes in Phase 3, shares sink 10% - CHOSUNBIZhttps://www.pharmaradar360.com/article/b-riley-initiates-4d-molecular-therapeutics-stock-coverage-with-buy-rating-ad56f6cebd905b8aPharma Surgeen2026-08-01T01:35:50.000ZB.Riley initiates 4D Molecular Therapeutics stock coverage with buy ratinghttps://www.pharmaradar360.com/article/medicines-misleading-ads-on-tukaram-mundhe-s-radar-maharashtra-fda-chief-says-721c22f1278de122Pharma Surgeen2026-08-01T01:30:01.000ZMedicines, Misleading Ads On Tukaram Mundhe's Radar? Maharashtra FDA Chief Says...https://www.pharmaradar360.com/article/fda-panel-backs-unapproved-peptides-despite-safety-concerns-22833d81f60e2149Pharma Surgeen2026-08-01T01:06:08.000ZFDA panel backs unapproved peptides despite safety concernshttps://www.pharmaradar360.com/article/chong-kun-dang-s-ckd-339-enters-phase-3-in-south-korea-for-patients-uncontrolled-c59cf42d98ced1e5Pharma Surgeen2026-08-01T00:45:00.000ZChong Kun Dang’s CKD-339 Enters Phase 3 in South Korea for Patients Uncontrolled on Monotherapyhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-raised-guidance-is-it-still-16-undervalued-028fc57a01f44af0Pharma Surgeen2026-08-01T00:43:41.000ZWest Pharmaceutical Services (WST) Raised Guidance, Is It Still 16% Undervalued?https://www.pharmaradar360.com/article/doctors-warn-against-most-powerful-weight-loss-jab-ever-as-users-exploit-legal-l-b413f0d5c1cb020fPharma Surgeen2026-08-01T00:01:00.000ZDoctors warn against 'most powerful weight-loss jab ever as users exploit legal loopholehttps://www.pharmaradar360.com/article/actinogen-medical-advances-pivotal-xanamia-trial-towards-november-readout-icymi-099bb910e9046a5fPharma Surgeen2026-08-01T00:00:33.000ZActinogen Medical advances pivotal XanaMIA trial towards November readout - ICYMIhttps://www.pharmaradar360.com/article/sns-74c7f276908b05f6Pharma Surgeen2026-08-01T00:00:00.000Z当社名をかたるSNSなりすましアカウントに関する注意喚起https://www.pharmaradar360.com/article/2026-96578fb344d8a6a9Pharma Surgeen2026-08-01T00:00:00.000Z「健康経営優良法人2026（大規模法人部門）」に認定https://www.pharmaradar360.com/article/s-p-global-sustainability-yearbook-member-2026-958ba77733f54961Pharma Surgeen2026-08-01T00:00:00.000ZS&P GlobalによるSustainability Yearbook Member 2026に選定https://www.pharmaradar360.com/article/0-5-4eb57423dee8c7f8Pharma Surgeen2026-08-01T00:00:00.000Zアレルギー性結膜炎治療剤「アレジオン®眼瞼クリーム0.5%」参天製薬と杏林製薬の日本における共同販売促進契約締結のお知らせhttps://www.pharmaradar360.com/article/stn1012700-ryjusea-0-25mg-ml-dd0933d811da22d9Pharma Surgeen2026-08-01T00:00:00.000Z近視の進行抑制を目的とする点眼剤STN1012700（Ryjusea 0.25mg/mL点眼液）についてアジア事業地域で初めてとなる販売承認をフィリピンで取得https://www.pharmaradar360.com/article/0-02-6419f044f53442e2Pharma Surgeen2026-08-01T00:00:00.000Z緑内障・高眼圧症治療剤「ロープレッサ®点眼液0.02%」国内における製造販売承認を取得https://www.pharmaradar360.com/article/db0b80c339aa9269Pharma Surgeen2026-08-01T00:00:00.000Z「ちびまる子ちゃん」と考える、子どもの近視 ― 日常の気づきから“まずは眼科へ”を伝える疾患啓発メッセージを全国に展開 ―https://www.pharmaradar360.com/article/santen-5-4ca46a96459c42cdPharma Surgeen2026-08-01T00:00:00.000ZSanten中国、5つの緑内障点眼薬について、中国本土における独占的な流通および販売促進に関する契約を締結https://www.pharmaradar360.com/article/0-1-c58398bfb5224414Pharma Surgeen2026-08-01T00:00:00.000Z後天性眼瞼下垂治療剤「アップニーク®ミニ点眼液0.1%」発売のお知らせhttps://www.pharmaradar360.com/article/05561923dc05a83aPharma Surgeen2026-08-01T00:00:00.000Z役員人事に関するお知らせhttps://www.pharmaradar360.com/article/8-b276e13c2c217314Pharma Surgeen2026-08-01T00:00:00.000Z＜花粉症に対する意識調査＞ 花粉症で「パフォーマンスに影響あり」は8割以上 「初期療法（早期治療）」を正しく知っている人の半数以上は「毎年実施」 ～眼科医と気象予報士が解説、花粉飛散期前の対策で春をより快適に～https://www.pharmaradar360.com/article/40-mg-ml-70160edfee675c11Pharma Surgeen2026-08-01T00:00:00.000Zアフリベルセプト硝子体内注射用キット40 mg/mL「バイエル」の発売予定についてhttps://www.pharmaradar360.com/article/2026-d377ede07642acf8Pharma Surgeen2026-08-01T00:00:00.000Z「2026年度 参天製薬奨学寄付プログラム」の募集は終了しましたhttps://www.pharmaradar360.com/article/refinement-of-operating-characteristics-for-model-based-tgi-metrics-decision-sup-95fbb815f42a5afdPharma Surgeen2026-08-01T00:00:00.000ZRefinement of Operating Characteristics for Model-Based TGI Metrics Decision Support to Ungate a Pivotal Trial in Oncology.https://www.pharmaradar360.com/article/a-bayesian-optimal-adaptive-clinical-trial-design-for-sequentially-integrated-th-67de5d5e76bcd1c3Pharma Surgeen2026-08-01T00:00:00.000ZA Bayesian Optimal Adaptive Clinical Trial Design for Sequentially Integrated Therapies.https://www.pharmaradar360.com/article/safety-tolerability-pharmacokinetics-food-effect-of-ribitol-and-its-effect-on-qt-87d288d261b77ab1Pharma Surgeen2026-08-01T00:00:00.000ZSafety, Tolerability, Pharmacokinetics, Food Effect of Ribitol, and Its Effect on QTcF in Healthy Adults: First-in-Human, Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled Studies.https://www.pharmaradar360.com/article/innovative-clinical-pharmacology-modeling-and-simulation-strategies-for-accelera-29ae1ba27af1eb12Pharma Surgeen2026-08-01T00:00:00.000ZInnovative Clinical Pharmacology, Modeling, and Simulation Strategies for Accelerating Rare Disease Drug Development.https://www.pharmaradar360.com/article/ssgj-613-alleviates-pain-and-reduces-the-risk-of-acute-flares-in-patients-with-g-bbb3fff8f5f5eee6Pharma Surgeen2026-08-01T00:00:00.000ZSSGJ-613 Alleviates Pain and Reduces the Risk of Acute Flares in Patients With Gout: A Randomized, Double-Blind, Phase II Study.https://www.pharmaradar360.com/article/trxr-inhibition-and-nrf2-foxo3-modulation-by-repurposed-drugs-a-redox-strategy-t-f9cf0206f0957603Pharma Surgeen2026-08-01T00:00:00.000ZTrxR Inhibition and Nrf2-FOXO3 Modulation by Repurposed Drugs: A Redox Strategy to Reverse Cancer Multidrug Resistance.https://www.pharmaradar360.com/article/effects-of-bifidobacterium-animalis-subsp-lactis-cp-9-on-gut-microbiota-and-immu-cfe106e47cd7ae69Pharma Surgeen2026-08-01T00:00:00.000ZEffects of Bifidobacterium animalis Subsp. Lactis CP-9 on Gut Microbiota and Immune Functions in Healthy Infants.https://www.pharmaradar360.com/article/pragmatic-two-stage-design-for-clinical-trials-with-treatment-selection-1a007a55796c2579Pharma Surgeen2026-08-01T00:00:00.000ZPragmatic Two-Stage Design for Clinical Trials With Treatment Selection.https://www.pharmaradar360.com/article/a-simulation-based-assessment-of-dosage-regimen-appropriateness-for-multiple-mye-3267327c98fbdd93Pharma Surgeen2026-08-01T00:00:00.000ZA Simulation-Based Assessment of Dosage Regimen Appropriateness for Multiple Myeloma Medicines Reflecting Demographic and Ethnic Differences.https://www.pharmaradar360.com/article/pharmacological-insights-and-clinical-challenges-of-wenxin-keli-in-arrhythmia-tr-7d8e4073b4a6df28Pharma Surgeen2026-08-01T00:00:00.000ZPharmacological Insights and Clinical Challenges of Wenxin Keli in Arrhythmia Treatment.https://www.pharmaradar360.com/article/safety-and-pharmacokinetics-of-olamkicept-doses-up-to-2400-mg-in-healthy-japanes-6c7c213d60381fe3Pharma Surgeen2026-08-01T00:00:00.000ZSafety and Pharmacokinetics of Olamkicept Doses up to 2400 mg in Healthy Japanese Men: Phase I, Randomized, Placebo-Controlled, and Double-Blind Trial.https://www.pharmaradar360.com/article/vobramitamab-duocarmazine-an-anti-b7-h3-antibody-drug-conjugate-in-patients-with-ba0cda32da4a1114Pharma Surgeen2026-08-01T00:00:00.000ZVobramitamab duocarmazine, an anti-B7-H3 antibody-drug conjugate, in patients with advanced solid tumors: Final results of a phase 1 cohort expansion.https://www.pharmaradar360.com/article/does-increasing-sample-size-inevitably-lead-to-statistical-significance-insights-3d2a138fb4013a78Pharma Surgeen2026-08-01T00:00:00.000ZDoes Increasing Sample Size Inevitably Lead to Statistical Significance? Insights From a Monte Carlo Simulation Study for Medical Research Design.https://www.pharmaradar360.com/article/safety-and-pharmacokinetics-of-single-and-multiple-ascending-doses-of-olamkicept-5b651181281b131ePharma Surgeen2026-08-01T00:00:00.000ZSafety and Pharmacokinetics of Single and Multiple Ascending Doses of Olamkicept up to 2400 mg in Healthy Men: Phase I, Randomized, Placebo-Controlled, and Double-Blind Trial.https://www.pharmaradar360.com/article/a-prospective-observational-study-of-anamorelin-during-chemoimmunotherapy-in-non-bbcbf572ba9f0f37Pharma Surgeen2026-08-01T00:00:00.000ZA Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non-Small Cell Lung Cancer With Cachexia (SPIRAL-ANA).https://www.pharmaradar360.com/article/dexamethasone-versus-placebo-in-comatose-survivors-of-out-of-hospital-cardiac-ar-e823b43db5cad9b1Pharma Surgeen2026-08-01T00:00:00.000ZDexamethasone Versus Placebo in Comatose Survivors of Out-of-Hospital Cardiac Arrest: Study Protocol for a Multicenter Randomized Comparison Within the Danish Out-of-Hospital Cardiac Arrest Trial (DANOHCA).https://www.pharmaradar360.com/article/prophylactic-olanzapine-versus-placebo-in-comatose-survivors-of-out-of-hospital-296f3b16b0b9f5f1Pharma Surgeen2026-08-01T00:00:00.000ZProphylactic Olanzapine Versus Placebo in Comatose Survivors of Out-of-Hospital Cardiac Arrest: Protocol for a Multicenter Randomized Comparison Within the Danish Out-of-Hospital Cardiac Arrest (DANOHCA) Trial.https://www.pharmaradar360.com/article/to-cluster-or-not-to-cluster-a-comparison-of-approaches-to-targeting-type-2-diab-c74dcb977b7bf79aPharma Surgeen2026-08-01T00:00:00.000ZTo Cluster or Not to Cluster? A Comparison of Approaches to Targeting Type 2 Diabetes Glucose-Lowering Therapy in the TriMaster Crossover Trial.https://www.pharmaradar360.com/article/weight-lowering-drugs-and-natural-female-fertility-a-systematic-review-and-meta-5fc1f96357007c58Pharma Surgeen2026-08-01T00:00:00.000ZWeight-Lowering Drugs and Natural Female Fertility-A Systematic Review and Meta-Analysis.https://www.pharmaradar360.com/article/differential-effects-of-sevoflurane-versus-propofol-on-calmodulin-expression-in-d5dc2bddf2b8178ePharma Surgeen2026-08-01T00:00:00.000ZDifferential effects of sevoflurane versus propofol on calmodulin expression in breast cancer patients.https://www.pharmaradar360.com/article/the-mechanisms-of-myricetin-and-quercetin-in-regulating-mirna-140-and-mmp-timp-s-80f58ace311997ffPharma Surgeen2026-08-01T00:00:00.000ZThe mechanisms of myricetin and quercetin in regulating miRNA-140 and MMP/TIMP signaling pathway in osteoarthritis treatment.https://www.pharmaradar360.com/article/efficacy-and-safety-of-gs1-144-a-novel-neurokinin-3-receptor-antagonist-for-mode-871d6d7bdf007ec0Pharma Surgeen2026-08-01T00:00:00.000ZEfficacy and safety of GS1-144, a novel neurokinin 3 receptor antagonist, for moderate-to-severe vasomotor symptoms associated with menopause in Chinese women: a randomized, double-blind, placebo-controlled phase 2 trial.https://www.pharmaradar360.com/article/accelerating-the-clinical-translation-of-antibody-drug-conjugates-in-pancreatobi-3d327cde6825226aPharma Surgeen2026-08-01T00:00:00.000ZAccelerating the Clinical Translation of Antibody-Drug Conjugates in Pancreatobiliary Cancers: A Comprehensive Clinical Trial Landscape Analysis Based on the Trialtrove Clinical Intelligence Database.https://www.pharmaradar360.com/article/phenotype-variability-in-interstitial-cystitis-clinical-trial-recruitment-7402ce417d4e535dPharma Surgeen2026-08-01T00:00:00.000ZPhenotype Variability in Interstitial Cystitis Clinical Trial Recruitment.https://www.pharmaradar360.com/article/incidentally-detected-dual-feeder-pulmonary-arteriovenous-malformation-mimicking-716460167a36c735Pharma Surgeen2026-08-01T00:00:00.000ZIncidentally Detected Dual-feeder Pulmonary Arteriovenous Malformation Mimicking a Pulmonary Mass on CT: A Case Reporthttps://www.pharmaradar360.com/article/a-case-of-lupus-erythematosus-panniculitis-of-the-abdominal-wall-imagingcytopath-0ca288ca16b5353dPharma Surgeen2026-08-01T00:00:00.000ZA Case of Lupus Erythematosus Panniculitis of the Abdominal Wall: Imagingcytopathological Associationhttps://www.pharmaradar360.com/article/magnesium-sulphate-versus-fentanyl-as-an-adjuvant-to-levobupivacaine-in-ultrasou-991c187465bf89dePharma Surgeen2026-08-01T00:00:00.000ZMagnesium Sulphate versus Fentanyl as an Adjuvant to Levobupivacaine in Ultrasoundguided Supraclavicular Brachial Plexus Block: A Randomised Controlled Studyhttps://www.pharmaradar360.com/article/inflammatory-cytokines-autoantibodies-and-salivary-gland-function-in-sjogren-s-s-09bac3e5141a15bbPharma Surgeen2026-08-01T00:00:00.000ZInflammatory cytokines, autoantibodies and salivary gland function in Sjögren’s syndrome: Effects of T. wilfordii as Hook F medical wine and tripterygium glycosides tabletshttps://www.pharmaradar360.com/article/bullying-in-predicting-gelotophobia-fear-of-ridicule-among-obese-women-attending-93fc6203f0120da1Pharma Surgeen2026-08-01T00:00:00.000Zالاسهام النسبي لاضطراب صورة الجسم والتنمر في التنبؤ برهاب الجيلوتوفوبيا(رهاب السخرية) لدى البدينات المترددات على مراكز علاج السمنة (دراسة سيكومترية- كلينيكية) bullying in predicting gelotophobia (fear of ridicule) among obese women attending obesity treatment centers (psychometric-clinical study)https://www.pharmaradar360.com/article/hemodynamic-response-to-intubation-with-4-different-laryngoscopes-in-coronary-ar-84cd19f6bcac26afPharma Surgeen2026-08-01T00:00:00.000ZHemodynamic Response to Intubation With 4 Different Laryngoscopes in Coronary Artery Bypass Graft Surgery: A Randomized Trialhttps://www.pharmaradar360.com/article/questioning-child-and-adolescent-sex-abuse-victims-at-trial-a-gender-based-inves-8b0bb9b43760550dPharma Surgeen2026-08-01T00:00:00.000ZQuestioning child and adolescent sex abuse victims at trial: A gender-based investigation.https://www.pharmaradar360.com/article/effect-of-transcript-length-temperature-and-lyophilization-on-mrna-lipid-nanopar-541a0d69e0d6e975Pharma Surgeen2026-08-01T00:00:00.000ZEffect of transcript length, temperature, and lyophilization on mRNA-lipid nanoparticle stabilityhttps://www.pharmaradar360.com/article/immunogenicity-and-safety-of-papilloguard-4-the-first-quadrivalent-hpv-vaccine-c-f52e53ab14ca053cPharma Surgeen2026-08-01T00:00:00.000ZImmunogenicity and safety of Papilloguard® 4, the first quadrivalent HPV vaccine combined with adjuvant system 04, versus Gardasil® in healthy 15–25-year-old individuals: a phase III, randomized, double-blind, non-inferiority trialhttps://www.pharmaradar360.com/article/broad-spectrum-antibiotic-prophylaxis-for-pancreatoduodenectomy-assessment-of-ea-56e62fa6f085ac6bPharma Surgeen2026-08-01T00:00:00.000ZBroad-spectrum antibiotic prophylaxis for pancreatoduodenectomy: Assessment of early adoption of randomized trial datahttps://www.pharmaradar360.com/article/looking-through-the-cracks-vulnerabilities-and-deprivation-in-the-brazilian-open-a3da9c3a8cde477dPharma Surgeen2026-08-01T00:00:00.000ZLooking through the cracks: vulnerabilities and deprivation in the Brazilian open drug sceneshttps://www.pharmaradar360.com/article/pregnancy-outcomes-following-eslicarbazepine-acetate-exposure-in-women-with-epil-17540b732ac91704Pharma Surgeen2026-08-01T00:00:00.000ZPregnancy outcomes following Eslicarbazepine acetate exposure in women with epilepsy: A global safety database analysis from clinical development to 16 years of post-marketing experiencehttps://www.pharmaradar360.com/article/targeting-pulmonary-vascular-alveolar-coupling-in-bronchopulmonary-dysplasia-the-3c4891c36f0884daPharma Surgeen2026-08-01T00:00:00.000ZTargeting pulmonary vascular–alveolar coupling in bronchopulmonary dysplasia: Therapeutic mechanisms and translational prospects of extracellular vesicle-based drug deliveryhttps://www.pharmaradar360.com/article/how-health-professionals-navigate-diagnostic-uncertainty-in-clinical-practice-a-b0c09bbb5021e09bPharma Surgeen2026-08-01T00:00:00.000ZHow health professionals navigate diagnostic uncertainty in clinical practice: A rapid scoping reviewhttps://www.pharmaradar360.com/article/reframing-immunonutrition-evidence-in-clinical-practice-a-call-for-standardised-03147c3319573e27Pharma Surgeen2026-08-01T00:00:00.000ZReframing immunonutrition evidence in clinical practice: A call for standardised mechanistic and outcome measureshttps://www.pharmaradar360.com/article/metabolic-adherence-and-sustainability-outcomes-of-plant-based-low-carbohydrate-f90223f6e14afa35Pharma Surgeen2026-08-01T00:00:00.000ZMetabolic, adherence, and sustainability outcomes of plant-based low-carbohydrate and ketogenic diets: A systematic review of clinical evidencehttps://www.pharmaradar360.com/article/biomarker-testing-among-patients-with-nonsquamous-nsclc-across-three-time-period-b9c42ffdb01f46eaPharma Surgeen2026-08-01T00:00:00.000ZBiomarker Testing Among Patients With Nonsquamous NSCLC Across Three Time Periods and Three Testing Platforms—A Brief Reporthttps://www.pharmaradar360.com/article/letter-to-the-editor-re-clinical-prediction-modeling-of-baseline-differential-re-ab1b81b6ad3a37f2Pharma Surgeen2026-08-01T00:00:00.000ZLetter to the Editor re: "Clinical prediction modeling of baseline differential renal function based on ultrasound in congenital unilateral ureteropelvic junction obstruction"https://www.pharmaradar360.com/article/interdisciplinary-intervention-gain-vs-enhanced-usual-care-for-reducing-severe-p-4caaf24e9e3d94caPharma Surgeen2026-08-01T00:00:00.000ZInterdisciplinary intervention (GAIN) vs. enhanced usual care for reducing severe post-concussion symptoms in adults 2–4 months post-injury: A stepped wedge cluster randomised controlled trialhttps://www.pharmaradar360.com/article/neighborhood-socioeconomic-deprivation-is-associated-with-operative-spinal-neopl-d58f7763298eef95Pharma Surgeen2026-08-01T00:00:00.000ZNeighborhood socioeconomic deprivation is associated with operative spinal neoplasms: a cross-sectional analysis of 1,038 patientshttps://www.pharmaradar360.com/article/assessing-the-assessors-comparative-performance-of-frailty-and-nutritional-metri-dc9cc99c1c8ffeb5Pharma Surgeen2026-08-01T00:00:00.000ZAssessing the Assessors: Comparative performance of frailty and nutritional metrics in predicting 30-Day morbidity and mortality after cranial neurosurgeryhttps://www.pharmaradar360.com/article/multi-strain-clostridioides-difficile-infection-increased-detection-and-clinical-b452f7baf62e4465Pharma Surgeen2026-08-01T00:00:00.000ZMulti-strain Clostridioides difficile infection: Increased detection and clinical implicationshttps://www.pharmaradar360.com/article/0512-guselkumab-for-the-treatment-of-guttate-and-plaque-psoriasis-a-prospective-f481f4941991eed6Pharma Surgeen2026-08-01T00:00:00.000Z0512 Guselkumab for the treatment of guttate and plaque psoriasis: A prospective trialhttps://www.pharmaradar360.com/article/fabrication-and-characterization-of-buccal-dissolving-microneedles-for-the-poten-24fa7d3c25944765Pharma Surgeen2026-08-01T00:00:00.000ZFabrication and Characterization of buccal dissolving microneedles for the potential management of Parkinson Diseasehttps://www.pharmaradar360.com/article/recent-advances-on-thermoresponsive-hydrogels-in-ophthalmology-with-specific-foc-206930c9e14b4403Pharma Surgeen2026-08-01T00:00:00.000ZRecent advances on thermoresponsive hydrogels in ophthalmology with specific focus on their applications in dry eye disease management: Current status and future prospectivehttps://www.pharmaradar360.com/article/thyroid-cancer-and-double-strand-dna-break-repair-the-potential-role-of-the-mrn-af929dad9dfe97cbPharma Surgeen2026-08-01T00:00:00.000ZThyroid cancer and double-strand DNA break repair: The potential role of the MRN complex pathogenic variantshttps://www.pharmaradar360.com/article/letter-to-the-editor-clinical-outcomes-of-early-fast-compared-to-slow-sodium-cor-aeeec81d6df84f87Pharma Surgeen2026-08-01T00:00:00.000ZLetter to the editor: “Clinical outcomes of early fast compared to slow sodium correction rate in adults with severe hypernatremia: A comparative effectiveness study”https://www.pharmaradar360.com/article/impact-of-cyst-maturity-on-drug-resistance-assays-in-acanthamoeba-genotype-t4-bb76a0dbe2c86c0dPharma Surgeen2026-08-01T00:00:00.000ZImpact of cyst maturity on drug resistance assays in Acanthamoeba Genotype T4https://www.pharmaradar360.com/article/anaphalis-margaritacea-ethanol-extract-exhibits-potent-anti-trichinella-spiralis-53182496667167ebPharma Surgeen2026-08-01T00:00:00.000ZAnaphalis margaritacea ethanol extract exhibits potent anti-Trichinella spiralis activity via mitochondrial dysfunction and host tissue protectionhttps://www.pharmaradar360.com/article/postoperative-effects-of-horizontal-platelet-rich-fibrin-after-impacted-third-mo-cbbc81e203c54248Pharma Surgeen2026-08-01T00:00:00.000ZPostoperative effects of horizontal platelet-rich fibrin after impacted third molar extraction: a randomized controlled trialhttps://www.pharmaradar360.com/article/ion-valency-driven-control-of-network-architecture-and-tissue-level-drug-transpo-ef0dfe43ef5010f4Pharma Surgeen2026-08-01T00:00:00.000ZIon valency–driven control of network architecture and tissue-level drug transport in protein-derived hydrogelshttps://www.pharmaradar360.com/article/tlr4-knockout-ameliorates-acute-lps-sensitized-tolvaptan-induced-idiosyncratic-l-d1f8dade3d3c2da2Pharma Surgeen2026-08-01T00:00:00.000ZTLR4 knockout ameliorates acute LPS-sensitized tolvaptan-induced idiosyncratic liver injury by disrupting drug metabolism, inflammation, and bile acid homeostasishttps://www.pharmaradar360.com/article/cd20-targeted-immunotherapies-in-b-cell-malignancies-mechanistic-and-clinical-ad-98894e2eb88fa8aePharma Surgeen2026-08-01T00:00:00.000ZCD20-targeted immunotherapies in B-cell malignancies: mechanistic and clinical advanceshttps://www.pharmaradar360.com/article/differences-in-reactive-metabolite-formation-and-cytochrome-p450-binding-between-b11bcef888756fcePharma Surgeen2026-08-01T00:00:00.000ZDifferences in reactive metabolite formation and cytochrome P450 binding between acetaminophen and its bicyclo[1.1.1]pentane bioisosterehttps://www.pharmaradar360.com/article/effects-of-different-exercise-modalities-and-doses-on-glycated-hemoglobin-in-pat-4df077c73f895635Pharma Surgeen2026-08-01T00:00:00.000ZEffects of different exercise modalities and doses on glycated hemoglobin in patients with type 2 diabetes mellitus and overweight or obesity: a systematic review and Bayesian multilevel network meta-analysishttps://www.pharmaradar360.com/article/prediabetes-in-ontario-improving-surveillance-for-better-disease-prevention-0b0a09f512e6fb48Pharma Surgeen2026-08-01T00:00:00.000ZPrediabetes in Ontario: improving surveillance for better disease preventionhttps://www.pharmaradar360.com/article/the-first-epidemiological-study-of-presymptomatic-type-1-diabetes-among-first-de-4ecb70e73204869fPharma Surgeen2026-08-01T00:00:00.000ZThe first epidemiological study of presymptomatic type 1 diabetes among first-degree relatives in Japan: PREP-T1D studyhttps://www.pharmaradar360.com/article/deep-learning-reconstruction-dual-energy-computed-tomography-for-gastrointestina-e4882da725ede1cdPharma Surgeen2026-08-01T00:00:00.000ZDeep learning reconstruction dual-energy computed tomography for gastrointestinal system tumors: low-kiloelectron volt imaging vs routine imaginghttps://www.pharmaradar360.com/article/prejudice-against-jagged-personality-profiles-rethinking-bias-in-psychological-r-701f102a64c81a8dPharma Surgeen2026-08-01T00:00:00.000ZPrejudice against jagged personality profiles: Rethinking bias in psychological research and clinical practicehttps://www.pharmaradar360.com/article/pharmaceutical-residues-as-emerging-contaminants-health-impacts-and-the-financia-bee473ea20cb4fb0Pharma Surgeen2026-08-01T00:00:00.000ZPharmaceutical residues as emerging contaminants: Health impacts and the financial burden of exposurehttps://www.pharmaradar360.com/article/risk-of-major-structural-birth-defects-following-repeat-mrna-covid-19-vaccinatio-556c78c6652d4737Pharma Surgeen2026-08-01T00:00:00.000ZRisk of major structural birth defects following repeat mRNA COVID-19 vaccination in the first trimester: a population-based cohort studyhttps://www.pharmaradar360.com/article/prognostic-value-of-the-geriatric-nutritional-risk-index-for-long-term-all-cause-5f076901580e68c2Pharma Surgeen2026-08-01T00:00:00.000ZPrognostic Value of the Geriatric Nutritional Risk Index for Long-Term All-Cause Mortality in Older Patients with Non-ST-Segment Elevation Myocardial Infarctionhttps://www.pharmaradar360.com/article/nutritional-prehabilitation-for-robot-assisted-radical-prostatectomy-a-proposed-7ca5e668204ad53fPharma Surgeen2026-08-01T00:00:00.000ZNutritional prehabilitation for robot-assisted radical prostatectomy: A proposed clinical framework integrating body composition analysishttps://www.pharmaradar360.com/article/medium-chain-triglyceride-supplementation-in-preterm-infants-a-prospective-cohor-206c83f8e0e7be79Pharma Surgeen2026-08-01T00:00:00.000ZMedium-chain triglyceride supplementation in preterm infants: A prospective cohort studyhttps://www.pharmaradar360.com/article/resting-state-eeg-for-continuous-prognostic-monitoring-and-prediction-of-coma-re-0f494b9c32f51545Pharma Surgeen2026-08-01T00:00:00.000ZResting-state EEG for continuous prognostic monitoring and prediction of coma recovery after acute brain injuryhttps://www.pharmaradar360.com/article/video-oculography-derived-oculomotor-indices-in-parkinson-s-disease-methodologic-f8595d6546ec9a73Pharma Surgeen2026-08-01T00:00:00.000ZVideo-oculography-derived oculomotor indices in Parkinson’s disease: Methodological limitations restrict clinical translationhttps://www.pharmaradar360.com/article/natural-history-and-radiological-features-of-rathke-s-cleft-cysts-diagnosed-on-m-365c4a11f4160e4bPharma Surgeen2026-08-01T00:00:00.000ZNatural history and radiological features of Rathke’s cleft cysts diagnosed on MRI: Analysis of 410 patients including 279 managed conservativelyhttps://www.pharmaradar360.com/article/safety-of-continuing-antithrombotic-therapy-during-lumboperitoneal-shunting-for-28cc2f907f5813bfPharma Surgeen2026-08-01T00:00:00.000ZSafety of continuing antithrombotic therapy during lumboperitoneal shunting for idiopathic normal pressure hydrocephalus: A single-center retrospective analysishttps://www.pharmaradar360.com/article/mri-assessed-small-vessel-disease-burden-and-gait-performance-in-post-ischemic-s-09147a9a1f8f6241Pharma Surgeen2026-08-01T00:00:00.000ZMRI-assessed small vessel disease burden and gait performance in post-ischemic stroke hemiparesishttps://www.pharmaradar360.com/article/when-findings-hurt-mental-health-effects-of-cerebral-mri-screening-in-patients-w-100222f99e1d3d95Pharma Surgeen2026-08-01T00:00:00.000ZWhen findings hurt: Mental health effects of cerebral MRI screening in patients with Hereditary Hemorrhagic Telangiectasiahttps://www.pharmaradar360.com/article/chronic-kidney-disease-does-not-influence-response-to-terlipressin-in-hepatorena-172043990c2c3e07Pharma Surgeen2026-08-01T00:00:00.000ZChronic Kidney Disease Does Not Influence Response to Terlipressin in Hepatorenal Syndrome–Acute Kidney Injuryhttps://www.pharmaradar360.com/article/ai-assisted-capsule-endoscopy-for-detection-of-ulcers-and-erosions-in-crohn-s-di-9c39a67ef3c8cc09Pharma Surgeen2026-08-01T00:00:00.000ZAI-Assisted Capsule Endoscopy for Detection of Ulcers and Erosions in Crohn’s Disease: A Multicenter Validation Studyhttps://www.pharmaradar360.com/article/fecal-microbiota-based-therapies-compared-to-fecal-microbiota-transplantation-fo-617e082daf2a0ac4Pharma Surgeen2026-08-01T00:00:00.000ZFecal Microbiota-Based Therapies Compared to Fecal Microbiota Transplantation for Preventing Recurrent C difficile Infectionhttps://www.pharmaradar360.com/article/multi-omics-biomarker-in-adrenocortical-carcinoma-a-clinical-chemistry-perspecti-ae02eedc1e89a100Pharma Surgeen2026-08-01T00:00:00.000ZMulti-omics biomarker in adrenocortical carcinoma: a clinical-chemistry perspectivehttps://www.pharmaradar360.com/article/deep-learning-framework-integrating-18f-fdg-pet-ct-and-clinical-data-for-early-p-148680b759ced19cPharma Surgeen2026-08-01T00:00:00.000ZDeep learning framework integrating 18F-FDG PET/CT and clinical data for early prediction of chemotherapy response in advanced breast cancerhttps://www.pharmaradar360.com/article/the-impact-of-food-advertising-on-children-s-daily-energy-intake-does-it-differ-e033c1f1e698fc6bPharma Surgeen2026-08-01T00:00:00.000ZThe impact of food advertising on children's daily energy intake: does it differ by advertising content, format, or participant characteristics? A cross-over randomised controlled trialhttps://www.pharmaradar360.com/article/emotions-documented-in-clinical-notes-an-interpretative-descriptive-study-b3aa88fc37d21b1dPharma Surgeen2026-08-01T00:00:00.000ZEmotions documented in clinical notes: An interpretative descriptive studyhttps://www.pharmaradar360.com/article/magnesium-sulfate-for-neuroprotection-approach-to-addressing-clinical-questions-60fe57492e860c25Pharma Surgeen2026-08-01T00:00:00.000ZMagnesium sulfate for neuroprotection: Approach to addressing clinical questionshttps://www.pharmaradar360.com/article/rethinking-the-impact-of-dietary-sodium-and-potassium-on-blood-pressure-to-advan-dd995e44325964cdPharma Surgeen2026-08-01T00:00:00.000ZRethinking the impact of dietary sodium and potassium on blood pressure to advance public healthhttps://www.pharmaradar360.com/article/development-and-clinical-validation-of-a-protocol-agnostic-machine-learning-plat-e9d7a1ba7fbd899cPharma Surgeen2026-08-01T00:00:00.000ZDevelopment and Clinical Validation of a Protocol-Agnostic Machine Learning Platform for Automated Treatment Planning in External Beam Radiation Therapyhttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-limited-2026-q2-results-earnings-call-presentatio-2d987125eebfb023Pharma Surgeen2026-07-31T23:09:47.000ZTeva Pharmaceutical Industries Limited 2026 Q2 - Results - Earnings Call Presentation (NYSE:TEVA) 2026-07-31https://www.pharmaradar360.com/article/zhejiang-tianyu-pharmaceutical-co-ltd-class-a-revenue-breakdown-szse-300702-50300990cfba0914Pharma Surgeen2026-07-31T22:13:59.000ZZhejiang Tianyu Pharmaceutical Co. Ltd. Class A Revenue Breakdown – SZSE:300702https://www.pharmaradar360.com/article/epi-biotech-co-ltd-revenue-breakdown-krx-446440-d2fcd77bdd048a51Pharma Surgeen2026-07-31T22:10:55.000ZEpi Biotech Co., Ltd. Revenue Breakdown – KRX:446440https://www.pharmaradar360.com/article/j-j-s-biotech-progress-could-punish-its-2027-profit-79a0c143ed981ccaPharma Surgeen2026-07-31T22:03:00.000ZJ&J’s biotech progress could punish its 2027 profithttps://www.pharmaradar360.com/article/ipo-news-he-mei-pharmaceutical-s-hong-kong-ipo-and-full-convertibility-of-its-do-e0eafefa7ae5dfbfPharma Surgeen2026-07-31T21:56:23.000ZIPO News | He Mei Pharmaceutical's Hong Kong IPO and full convertibility of its domestically held unlisted shares have received filing confirmation from the China Securities Regulatory Commission (CSRC).